ClinicalTrials.gg
RecruitingNCT07053358Updated Mar 10, 2026

Safety and Efficacy Evaluation of LX111 Gene Therapy in nAMD Patients

An Early Phase 1 interventional study of LX111 Injection in Neovascular Age-related Macular Degeneration, sponsored by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine. Recruiting at 1 site in China. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-03-10.

Sponsored by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 107 studies in Macular Degeneration with a site in China — 36 open to participants now, 43 under way, 9 of them phase 3. Macular Degeneration · China.

Planned enrollment
85th of 91
10 · median 62
Started
2025
with 14 others
Phase 1
20 of 107
5 open now
Primary completion
2026-11
later than 22 of 42 live
Registered
92nd of 107
by date
Lead sponsor
5 of 107
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Among the 107 studies in Macular Degeneration with a site in China, this one is the 85th largest by planned enrollment of the 91 interventional ones that give a count, is one of 15 that started in 2025, is one of 20 in phase 1, reaches primary completion later than 22 of the 42 other live ones, and was the 92nd registered.

Macular Degeneration

1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

36 of the 107 studies in Macular Degeneration with a site in China are open now. Recruiting first, the newest first:

30 more — sign in →

All 36 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 167 Macular Degeneration studies recruiting now, 118 (71%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 107 studies in Macular Degeneration with a site in China, or all of them as a file.
02

Study summary

The goal of this study is to evaluate the safety and efficacy of LX111 treatment of nAMD. This study will enroll subjects aged ≥ 50 vears old to receive a single unilateral intravitreal (lVT) injection of LX111 to evaluate its safety and efficacy.

03

Conditions studied

  • Neovascular Age-related Macular Degeneration
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing to sign the , and willing to attend follow-up visits.
  2. Age ≥ 50
  3. Diagnosis of active CNV secondary to neovascular AMD
  4. BCVA ETDRS letters between 5 and 63
  5. Subjects must have received a minimum of 2 injections within 6 months prior to screening and demonstrated a meaningful response to anti-VEGF therapy
  6. Male subjects whose partner is a fertile female or female subjects who are fertile, agree to take effective measures from the screening period until the last follow-up.

Exclusion criteria

Exclusion Criteria:

  1. CNV or macular edema in the study eye secondary to diseases other than nAMD
  2. Retinal detachment, uveitis, uncontrolled glaucoma in the study eye, or any condition preventing visual acuity improvement
  3. Acute coronary syndrome, myocardial infarction or coronary artery revascularization, CVA, in the last 6 months
  4. Uncontrolled hypertension defined as average SBP ≥160 mmHg or an average DBP ≥100 mmHg
  5. Uncontrolled diabetes defined as >8.0% within 28 days prior to screening
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    LX111 intravitreal injections

    Genetic: LX111 Injection

Interventions

  • GeneticLX111 Injection

    Qualified subjects will receive a single unilateral intravitreal injection of LX111 at Day 0.

06

What researchers measure

Primary outcomes

  1. Adverse events and serious adverse events in the eyes and throughout the body within 364 days after LX111 treatment

    Incidence of adverse events and serious adverse events within 52 weeks of LX111 intravitreal injection in each dose group.

    Time frame: 52 weeks

  2. Dose Limiting Toxicity

    The incidence of DLT in each dose group.

    Time frame: 4 weeks

Secondary outcomes

  1. Mean changes in BCVA from Baseline

    The mean changes of BCVA scores on the ETDRS chart at different timepoints after LX111 treatment compared with baseline.

    Time frame: 12 weeks, 36 weeks, 52 weeks

  2. Mean changes in Central Subfield Thickness (CST) from Baseline

    The mean changes of CST at different timepoints after LX111 treatment compared with baseline.

    Time frame: 12 weeks, 36 weeks, 52 weeks

  3. The percentage of subjects who received anti-VEGF supplemental injection within 52 weeks after LX111 treatment

    The proportion of subjects who received anti-VEGF supplemental injection within 52 weeks after LX111 treatment

    Time frame: 52 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Nov 2026, 16 months after the start.

Of 75 phase 1 interventional studies under Macular Degeneration, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 30. This study's planned 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2025
First posted
Jul 8, 2025
StartActual
Jul 2, 2025
Primary completionEst.
Nov 23, 2026
CompletionEst.
Dec 30, 2029
Last update
Mar 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07053358
Collaborators
Innostellar Biotherapeutics Co.,Ltd
Responsible party
Xiaodong Sun (PhD, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine) — Principal investigator
First posted
Jul 8, 2025
Start date
Jul 2, 2025
Primary completion
Nov 23, 2026 (estimated)
Completion
Dec 30, 2029 (estimated)
Last update
Mar 10, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion